Navigation Links
CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas' Tender Offer
Date:2/27/2009

re inadequately controlled or intolerant to first-line anti anginal therapies. CV Therapeutics also has other clinical and preclinical drug development candidates and programs.

Additional Information

Stockholders of CV Therapeutics are advised to read CV Therapeutics' Schedule 14D-9 statement, when it becomes available, regarding the tender offer, because it will contain important information. Stockholders may obtain a free copy of the statement at the SEC's website at www.sec.gov. Stockholders may also obtain, without charge, a copy of the statement from MacKenzie Partners, Inc., which is assisting the company, by calling 800-322-2885 toll free or by calling 212-929-5500 or by emailing cvtx@mackenziepartners.com.

Except for the historical information contained herein, the matters set forth in this press release, including statements as to research and development and commercialization of products, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including operating losses and fluctuations in operating results; capital requirements; regulatory review and approval of our products; the conduct and timing of clinical trials; commercialization of products; market acceptance of products; product labeling; concentrated customer base; reliance on strategic partnerships and collaborations; uncertainties in drug development; uncertainties regarding intellectual property and other risks detailed from time to time in CV Therapeutics' SEC reports, including its Annual Report on Form 10-K for the year ended December 3
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 2014  United Therapeutics Corporation (NASDAQ: ... its second quarter 2014 financial results before market ... United Therapeutics will host a half-hour teleconference on ... Time.  The teleconference is accessible by dialing 1-877-351-5881, ... the teleconference will be available for one week ...
(Date:7/22/2014)... PLAINS, New Jersey , 22. Juli 2014 ... für die Life-Sciences-Industrie, hat die Ernennung von Marcus ... bekanntgegeben. Herr Bergler hat die europäischen kommerziellen ... Lösungen unterstützt. Bevor er sich Qforma anschloss, war ... bei Cegedim Customer Information, als Vertriebsteam-Leiter Deutschland bei ...
(Date:7/22/2014)... Sunnyvale, CA (PRWEB) July 22, 2014 ... begin on September 9th, 2014 and will comprise of ... and Application’ classes. The TechTrainings is a series of ... professionals, designed to help them reach the next step ... SAS class is taught by Jennifer Kang, Senior ...
(Date:7/21/2014)... July 21, 2014 Lawrence ... Investment Board (WIB) and Las Positas College (LPC) ... technical education and hands-on training for veterans, officials ... Program at Las Positas is designed to ... for engineering technician careers, and establishes a pipeline ...
Breaking Biology Technology:Qforma gibt Schaffung des neuen Postens als General Manager in Europa bekannt 2Clinovo TechTrainings: Next Session of SAS and CDISC Classes Start 9th September, 2014 2Clinovo TechTrainings: Next Session of SAS and CDISC Classes Start 9th September, 2014 3Engineering Program Established for Veterans 2Engineering Program Established for Veterans 3
... 2012  MiMedx Group, Inc. (OTCBB: MDXG), an integrated ... biomaterials and bioimplants processed from human amniotic membrane, ... agreement with Systagenix, whereby Systagenix will co-market EpiFix®. ... processed from amniotic tissue, EpiFix® offers a wide ...
... Centre (CNIO) routinely runs such tests on samples sent in ... first step towards a truly personalised medicine. And researchers are ... organism at a molecular scale: the genes that are being ... through the bloodstream; and the length of the telomeres capping ...
... WASHINGTON -- Advisor to President Barack Obama for the ... Holdren visited the Navy,s corporate laboratory, March 16, to ... Research (LASR) and tour the sprawling 130-acre Washington, D.C., ... the Navy, Marine Corps and our Nation in ever ...
Cached Biology Technology:MiMedx Signs Agreement with Systagenix for Global Distribution of EpiFix® 2MiMedx Signs Agreement with Systagenix for Global Distribution of EpiFix® 3CNIO researchers take part in the most comprehensive personalized medicine study performed to date 2CNIO researchers take part in the most comprehensive personalized medicine study performed to date 3White House S&T advisor the Honorable Dr. John Holdren tours Naval Research Laboratory 2
(Date:7/22/2014)... schoolyards that feature natural habitats and trees and not ... inattention, according to a University of Colorado Boulder study. ... settings also provide stress-reducing benefits for youth, according to ... Place. The study is one of the first ... student access to green settings and stress. , "Many ...
(Date:7/22/2014)... meerkats which sees them prevent their daughters from breeding, ... study. , Research into the desert creatures which live ... helpers shows that the alpha female can flourish when ... shows how this way of life, also found in many ... its sinister side. , Dominant meerkats control breeding within ...
(Date:7/22/2014)... the the genus of planthopper known as Conosimus, which ... recently discovered in the southern part of the Iberian ... of it appears in the open-access Journal of ... new species, Conosimus baenai , has been named ... to the taxonomy of Iberian Hemiptera. , Conosimus ...
Breaking Biology News(10 mins):Natural-terrain schoolyards reduce children's stress, says Colorado University-Boulder study 2Natural-terrain schoolyards reduce children's stress, says Colorado University-Boulder study 3
... had knee replacement surgery -- finally able to walk and ... on pounds, but surprisingly that,s not the case, according to ... Lynn Snyder-Mackler in the Department of Physical Therapy in UD,s ... in the first few weeks after total knee arthroplasty (TKA), ...
... have shown multiple sclerosis (MS) patients are more often born ... is an environmental risk factor for the disease. A paper ... by Emmanuelle Waubant and Ellen Mowry, now suggests that this ... In many European populations, the HLA-DRB1*15 allele of this gene ...
... Journal of Clinical Endocrinology & Metabolism , shows that ... and reduced bone size in their grandsons. "This is ... has been demonstrated across two generations," says associate professor Mattias ... "This new risk factor may be significant for the diagnosis ...
Cached Biology News:Most patients gain weight after getting a new knee, UD study finds 2Grandpa's broken hip may mean weaker bones for his grandsons 2
Human plasmacytoid dendritic cells, BDCA-4+, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Dendritic Cells and EPCs...
Umbilical cord blood CD19+ B cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Monocytes, B Cells and NK Cells...
Umbilical cord blood CD4+ T cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood MNCs and T Cells...
Human peripheral blood CD56+ NK cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Monocytes, B Cells, NK Cells and Stem Cells...
Biology Products: